Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis

被引:53
|
作者
Galvin, Zita [1 ,2 ]
Rajakumar, Ramraj [1 ]
Chen, Emily [1 ]
Adeyi, Oyedele [1 ,2 ]
Selzner, Markus [1 ,3 ]
Grant, David [1 ,3 ]
Sapisochin, Gonzalo [1 ,3 ]
Greig, Paul [1 ,3 ]
Cattral, Mark [1 ,3 ]
McGilvray, Ian [1 ,3 ]
Ghanekar, Anand [1 ,3 ]
Selzner, Nazia [1 ,2 ]
Lilly, Les [1 ,2 ]
Patel, Keyur [1 ,2 ]
Bhat, Mamatha [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Univ Hlth Network, Div Gastroenterol & Hepatol, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Dept Surg, Toronto, ON, Canada
关键词
SIMPLE NONINVASIVE INDEX; HEPATITIS-C VIRUS; METABOLIC SYNDROME; CRYPTOGENIC CIRRHOSIS; SCORING SYSTEM; STEATOHEPATITIS; NAFLD; RISK; PROGRESSION; VALIDATION;
D O I
10.1002/lt.25338
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) can occur de novo in patients undergoing liver transplantation (LT) for indications other than NAFLD, and it has been increasingly recognized as a complication in the post-LT setting. This study aims to better characterize de novo NAFLD after LT by identifying risk factors for its development, describing incidence and extent of fibrosis, assessing the diagnostic utility of noninvasive serum fibrosis algorithms, and comparing survival to those without NAFLD. This was a retrospective single-center analysis of de novo NAFLD in a post-LT cohort. Those whose primary indication for LT was nonalcoholic steatohepatitis (NASH) were excluded. Risk factors were analyzed by univariate and multivariate analyses. De novo NAFLD and fibrosis were assessed on posttransplant liver biopsies, and noninvasive fibrosis scores were calculated from concomitant blood tests. After applying the exclusion criteria, 430 for-cause post-LT biopsies were evaluated; 33.3% (n = 143) had evidence of de novo steatosis and/or NASH at a median of 3.0 years after transplant. On multivariate analysis, body mass index (BMI; odds ratio [OR], 1.12; P < 0.001), diabetes mellitus (OR, 3.01; P = 0.002), hepatitis C virus (OR, 4.61; P < 0.001), weight gain (OR, 1.03; P = 0.007), and sirolimus use (OR, 3.11; P = 0.02) were predictive of de novo NAFLD after LT. Significant fibrosis (>= F2) was present in almost 40% of the cohort. Noninvasive serum fibrosis scores were not useful diagnostic tests. There was no significant difference in the short-term or longterm survival of patients who developed de novo NAFLD. In conclusion, diabetes, BMI, weight gain after LT, and sirolimus-based immunosuppression, in keeping with insulin resistance, were the only modifiable factors associated with development of de novo NAFLD. A significant proportion of patients with de novo NAFLD had fibrosis and given the limited utility of noninvasive serum fibrosis algorithms, alternative noninvasive tools are required to screen for fibrosis in this population. There was no significant difference in the short-term or longterm survival of patients who developed de novo NAFLD.
引用
收藏
页码:56 / 67
页数:12
相关论文
共 50 条
  • [1] Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis
    Choudhary, Narendra S.
    Saigal, Sanjiv
    Saraf, Neeraj
    Soin, Arvinder S.
    [J]. LIVER TRANSPLANTATION, 2019, 25 (06) : 967 - 968
  • [2] Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis Reply
    Lynch, Raymond J.
    Ye, Fei
    Sheng, Quanhu
    Zhao, Zhiguo
    Karp, Seth J.
    [J]. LIVER TRANSPLANTATION, 2019, 25 (06) : 971 - 973
  • [3] de novo nonalcoholic fatty liver disease after liver transplantation
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    [J]. LIVER TRANSPLANTATION, 2007, 13 (06) : 788 - 790
  • [4] Prevalence and predictors of de novo nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) after orthotopic liver transplantation (OLT)
    Seo, Suk
    Maganti, Kalyani
    Khehra, Manjit
    Ramsamooj, Rajendra
    Tsodikov, Alexander
    Torok, Natalie
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A789 - A789
  • [5] Recurrent or De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation: Natural History Based on Liver Biopsy Analysis
    Vallin, Melanie
    Guillaud, Olivier
    Boillot, Olivier
    Hervieu, Valerie
    Scoazec, Jean-Yves
    Dumortier, Jerome
    [J]. LIVER TRANSPLANTATION, 2014, 20 (09) : 1064 - 1071
  • [6] Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease
    Yalamanchili, Kanthi
    Saadeh, Sherif
    Klintmalm, Goeran B.
    Jennings, Linda W.
    Davis, Gary L.
    [J]. LIVER TRANSPLANTATION, 2010, 16 (04) : 431 - 439
  • [7] De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors
    Tejedor-Tejada, Javier
    Fuentes Valenzuela, Esteban
    Najera Munoz, Rodrigo
    Hernandez Gomez, Laura
    Garcia-Pajares, Felix
    Almohalla Alvarez, Carolina
    Sanchez-Martin, Fatima
    Alonso-Martin, Carmen
    Sanchez-Antolin, Gloria
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 399 - 406
  • [8] De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
    Han, Ma Ai Thanda
    Olivo, Raquel
    Choi, Catherine J.
    Pyrsopoulos, Nikolaos
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (12) : 1991 - 2004
  • [9] Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
    Dixon, JB
    Bhathal, PS
    O'Brien, PE
    [J]. GASTROENTEROLOGY, 2001, 121 (01) : 91 - 100
  • [10] De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
    Ma Ai Thanda Han
    Raquel Olivo
    Catherine J Choi
    Nikolaos Pyrsopoulos
    [J]. World Journal of Hepatology, 2021, 13 (12) : 1991 - 2004